Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + selumetinib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + selumetinib is an investigational combination therapy consisting of the chemotherapeutic agent docetaxel and the MEK1/2 inhibitor selumetinib. Docetaxel is a taxane-class cytotoxic drug that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. Selumetinib (also known as AZD6244 or ARRY-142886) is a selective small molecule inhibitor of MEK1/2, key kinases in the MAPK/ERK signaling pathway downstream of KRAS. The combination has been studied primarily in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring KRAS mutations, as well as in other solid tumors with RAS pathway alterations. While early-phase studies suggested improved progression-free survival and objective response rates compared to docetaxel alone, later phase III trials did not demonstrate significant improvement in overall survival or progression-free survival for this combination over standard chemotherapy[1][2][4][5]. The regimen has also been evaluated for safety and tolerability in different populations[6][7].
- Brand names
- TaxotereKoselugo
- Other names
- docetaxel + selumetinib
02
Targets
TUBB (Tubulin (alpha and beta subunits))MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on docetaxel + selumetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + selumetinib.